CASTLE BIOSCIENCES INC 8K

Castle Biosciences furnished an investor presentation outlining its Q1 2026 operating and financial performance, raised 2026 revenue guidance, and detailed progress across its diagnostic test portfolio and strategy.

Castle Biosciences, Inc. furnished an investor presentation as an exhibit to its Form 8-K, providing an update on its business, clinical portfolio and first quarter 2026 financial results, including total revenue of $83.7 million, strong growth in test volumes for its core products DecisionDx-Melanoma and TissueCypher, updated 2026 total revenue guidance raised to a range of $345–355 million, non-GAAP metrics such as adjusted gross margin of 75.6% and adjusted EBITDA of negative $5.1 million, and commentary on its capital allocation strategy, cash position of $261.7 million as of March 31, 2026, and ongoing clinical and market development activities across its dermatology, gastroenterology, and ophthalmology franchises.

Filing Facts

CIK

1447362

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-031255

Alert Tier

6